

CSE Symbol: IME
OTC PINK Symbol: IMEXF
Frankfurt/Stuttgart Stock Exchanges: DPD2

NR-2016-IME-28

Annual General Meeting Results

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in the early detection of bladder cancer through endoscopes.

Vancouver, B.C. and Boston, MA, December 14, 2016 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) reports that its shareholders approved all resolutions presented to them at its Annual General Meeting (the “Meeting”) held on December 13, 2016. Jim Hutchens, Robin Atlas, Steven Chan, Kenneth Daignault and Bill Galine were elected directors for the ensuing year. The shareholders also appointed De Visser Gray, LLP as auditors of the Company.

Subsequent to the Meeting, the Board of Directors appointed Jim Hutchens as President & CEO, Jorge Avelino as Chief Financial Officer, and William Galine as Corporate Secretary.

About Imagin Medical

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com.

ON BEHALF OF THE BOARD:

Jim Hutchens,
President & CEO

For further information, contact:

Bill Galine, Investor Relations
Telephone: (775) 737-3292
Email: billgaline@gmail.com

The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.